Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immune System Diseases AND Graft Versus Host Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    60 result(s) found for: Immune System Diseases AND Graft Versus Host Disease. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2015-001550-14 Sponsor Protocol Number: ECP-GVHD1 Start Date*: 2015-06-09
    Sponsor Name:Bispebjerg hospital
    Full Title: Extracorporeal Photopheresis Treatment in steroid refractory acute and chronic Graft versus Host Disease
    Medical condition: Acute and chronic Graft versus Host Disease (GVHD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004529-57 Sponsor Protocol Number: EQ-100-02 Start Date*: 2022-06-24
    Sponsor Name:Equillium Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
    Medical condition: Acute Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10018799 GVHD LLT
    22.0 100000004865 10059044 Allogeneic peripheral hematopoietic stem cell transplant LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022780-35 Sponsor Protocol Number: 10-005 Start Date*: 2011-07-06
    Sponsor Name:THERAKOS, Inc.
    Full Title: A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX™ for the Treatment of Patients with Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)
    Medical condition: Chronic graft-versus-host disease (cGvHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004847-35 Sponsor Protocol Number: PredEver_first Start Date*: 2012-09-07
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first) - A prospective multicenterphase IIA study -
    Medical condition: chronic Graft versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10018799 GVHD LLT
    14.1 10021428 - Immune system disorders 10063109 Transfusion associated GVHD LLT
    14.1 10021428 - Immune system disorders 10068907 CGVHD LLT
    14.1 10021428 - Immune system disorders 10018653 Graft-versus-host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004310-14 Sponsor Protocol Number: TJB0703 Start Date*: 2007-12-13
    Sponsor Name:CHU-ULG
    Full Title: Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II study
    Medical condition: Steroid resistant grade II to IV acute graft-versus-host disease (GVHD) or poor graft function after allogeneic hematopoietic cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10001756 Allogenic bone marrow transplantation therapy PT
    21.1 10042613 - Surgical and medical procedures 10045553 Unrelated donor bone marrow transplantation therapy PT
    20.0 10021428 - Immune system disorders 10018799 GVHD LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000894-22 Sponsor Protocol Number: MAGIC-HR-ECP Start Date*: 2019-12-10
    Sponsor Name:Department of Stem Cell Transplantation - University Medical Center Hamburg-Eppendorf
    Full Title: Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease
    Medical condition: New onset high risk acute GvHD following allogeneic SCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10018653 Graft-versus-host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018594-37 Sponsor Protocol Number: EMN-alloRIC2010 Start Date*: 2013-01-24
    Sponsor Name:European Myeloma Network
    Full Title: European Myeloma Network sequential phase I / phase II trial on RIC allogeneic transplantation: an optimized program for high risk relapsed patients
    Medical condition: Allogeneic transplantation for patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10059041 Allogeneic peripheral haematopoietic stem cell transplant LLT
    14.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004806-14 Sponsor Protocol Number: TKS-2014-001 Start Date*: Information not available in EudraCT
    Sponsor Name:Therakos, Inc.
    Full Title: Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute ...
    Medical condition: Acute graft-versus-host disease (aGvHD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (Completed) IT (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004267-20 Sponsor Protocol Number: RIG-P000814 Start Date*: 2016-09-01
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Multicenter, randomized Phase 2 Trial to determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) versus BAT in Steroid-refractory acute Graft-versus-Host Disease (aGvHD)
    Medical condition: Steroid-refractory acute Graft-versus-Host Disease (GvHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10018799 GVHD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000329-29 Sponsor Protocol Number: CSL964_2001 Start Date*: 2019-05-31
    Sponsor Name:CSL Behring LLC
    Full Title: A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versus-host disease in patients ...
    Medical condition: Graft versus host disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003237-33 Sponsor Protocol Number: HO112 Start Date*: 2013-11-21
    Sponsor Name:HOVON Foundation
    Full Title: Treatment of severe GVHD after allogeneic hematopoietic stem cell transplanatation with MSCs and steroid versus steroids alone. A prospective double-blind placebo-controlled randomized phase III t...
    Medical condition: Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    18.0 10021428 - Immune system disorders 10068908 AGVHD LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-000538-78 Sponsor Protocol Number: INCB39110-301 Start Date*: 2017-09-14
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host Disease
    Medical condition: Male or female, 18 years of age or older who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    20.1 10021428 - Immune system disorders 10066262 Acute graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10066263 Acute graft versus host disease in liver PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) BE (Completed) AT (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) GR (Completed) FI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005009-24 Sponsor Protocol Number: INO-0107 Start Date*: 2008-05-15
    Sponsor Name:EUSA Pharma
    Full Title: An international randomised, multicentre, parallel-group, Phase III comparative study of inolimomab against usual care in the Treatment of Primary Steroid Refractory Acute Graft versus Host Disease...
    Medical condition: Steroid refractory acute Graft versus Host Disease (aGvHD) after Allogeneic Haematopoietic Stem Cell Transplantation in adult patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004915-30 Sponsor Protocol Number: HO113 Start Date*: 2013-09-05
    Sponsor Name:HOVON Foundation
    Full Title: Treatment of severe steroid-refractory acute GvHD with mesenchymal stromal cells. A phase III, randomized double-blind multi-center HOVON study.
    Medical condition: Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    19.1 10021428 - Immune system disorders 10068908 AGVHD LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) BE (Completed) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000068-27 Sponsor Protocol Number: XEN/TG-001 Start Date*: 2013-11-29
    Sponsor Name:Xenikos BV
    Full Title: A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-vers...
    Medical condition: Acute Graft-versus-Host Disease (GVHD) not responding on regular first line therapy of 2 mg/kg corticosteroids daily.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10068908 AGVHD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001606-29 Sponsor Protocol Number: INCB39110-309 Start Date*: 2019-04-03
    Sponsor Name:Incyte Corporation
    Full Title: GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
    Medical condition: Moderate or severe cGVHD
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    20.1 10021428 - Immune system disorders 10072160 Chronic graft versus host disease in liver PT
    20.1 10021428 - Immune system disorders 10072158 Chronic graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10072159 Chronic graft versus host disease in skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) SE (Completed) DE (Prematurely Ended) PL (Completed) DK (Completed) ES (Temporarily Halted) GR (Prematurely Ended) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005659-19 Sponsor Protocol Number: RG_14-287 Start Date*: 2015-10-21
    Sponsor Name:University of Birmingham
    Full Title: A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed therapy with corticosteroids
    Medical condition: Chronic Graft versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2024-000203-67 Sponsor Protocol Number: DRI17633 Start Date*: 2024-04-30
    Sponsor Name:Kadmon Corporation, LLC
    Full Title: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (Th...
    Medical condition: Chronic graft-versus-host-disease
    Disease: Version SOC Term Classification Code Term Level
    27.0 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-004588-29 Sponsor Protocol Number: TA799-101 Start Date*: 2022-02-01
    Sponsor Name:VectivBio AG
    Full Title: A randomized, single-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease ...
    Medical condition: Acute graft versus host disease (aGVHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10075160 Graft versus host disease in gastrointestinal tract PT
    20.0 10021428 - Immune system disorders 10075161 Graft versus host disease in GI tract LLT
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PT (Prematurely Ended) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002253-30 Sponsor Protocol Number: INCB39110-120 Start Date*: 2019-07-01
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in...
    Medical condition: Male or female, 28 days to less than 18 years of age, who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    20.1 10021428 - Immune system disorders 10066262 Acute graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10066263 Acute graft versus host disease in liver PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 14 18:56:33 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA